Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply
The EPIC study investigators were aware of the prior cardiac studies cited by Drs Kenter and Cohen suggesting nephrotoxicity due to poloxamer 188. It is important to note that these early studies used commercial-grade poloxamer 188. Subsequent studies showed that removal of impurities from this prep...
Gespeichert in:
Veröffentlicht in: | JAMA : the journal of the American Medical Association 2021-09, Vol.326 (10), p.974 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 10 |
container_start_page | 974 |
container_title | JAMA : the journal of the American Medical Association |
container_volume | 326 |
creator | Kenter, Marcel J H Cohen, Adam F Gurkan, Umut A Casella, James F Kronsberg, Shari S Gorney, Rebecca T |
description | The EPIC study investigators were aware of the prior cardiac studies cited by Drs Kenter and Cohen suggesting nephrotoxicity due to poloxamer 188. It is important to note that these early studies used commercial-grade poloxamer 188. Subsequent studies showed that removal of impurities from this preparation reduced nephrotoxicity in a rat model and that the isolated impurities caused nephrotoxity. A phase 1 study of the resulting purified poloxamer 188 for acute chest syndrome in 43 participants with SCD focused on safety and included studies of urinary N-acetylglucosaminidase, retinol-binding protein, creatinine and creatinine clearance, albumin, and IgG excretion; participants were followed up for up to 10 days with repeat measurements at 28 to 35 days. The investigators concluded that there were no time-related increases in serum creatinine or creatinine clearance and no evidence of adverse effects on glomerular integrity, permeability, filtration, or proximal or distal tubular function. Phase 2 and 3 studies of purified poloxamer 188 for vaso-occlusive episodes in SCD also showed no evidence of nephrotoxicity based on serum creatinine levels. The effects of poloxamer 188 on the kidney are more fully explained in Supplement 3 of our article. |
doi_str_mv | 10.1001/jama.2021.11097 |
format | Article |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2577528239</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2577528239</sourcerecordid><originalsourceid>FETCH-proquest_journals_25775282393</originalsourceid><addsrcrecordid>eNrdjb1OwzAURg0CifAzs16JOamdNLIzolDEwBDRCsbKJDeqw60dfJMK3p4OPAAz33KGc6RPiFslMyWlWgx2b7Nc5ipTSlb6VCSqLExalJU5E4mUlUn10iwvxCXzII9ThU5OnptA4cvuMYIyBg4MDdkW3wP0IUJjne9nglfLIQ1tSzO7A8JqdBw6ZHAe6p2jLqIH6zu472aaGN7ctIO1az8IoUYieHCMlnHxb8_SFxzp-1qc95YYb355Je4eV5v6KR1j-JyRp-0Q5uiPapuXWpe5yYuq-Fv1A_fpniA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2577528239</pqid></control><display><type>article</type><title>Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply</title><source>American Medical Association Journals</source><creator>Kenter, Marcel J H ; Cohen, Adam F ; Gurkan, Umut A ; Casella, James F ; Kronsberg, Shari S ; Gorney, Rebecca T</creator><creatorcontrib>Kenter, Marcel J H ; Cohen, Adam F ; Gurkan, Umut A ; Casella, James F ; Kronsberg, Shari S ; Gorney, Rebecca T</creatorcontrib><description>The EPIC study investigators were aware of the prior cardiac studies cited by Drs Kenter and Cohen suggesting nephrotoxicity due to poloxamer 188. It is important to note that these early studies used commercial-grade poloxamer 188. Subsequent studies showed that removal of impurities from this preparation reduced nephrotoxicity in a rat model and that the isolated impurities caused nephrotoxity. A phase 1 study of the resulting purified poloxamer 188 for acute chest syndrome in 43 participants with SCD focused on safety and included studies of urinary N-acetylglucosaminidase, retinol-binding protein, creatinine and creatinine clearance, albumin, and IgG excretion; participants were followed up for up to 10 days with repeat measurements at 28 to 35 days. The investigators concluded that there were no time-related increases in serum creatinine or creatinine clearance and no evidence of adverse effects on glomerular integrity, permeability, filtration, or proximal or distal tubular function. Phase 2 and 3 studies of purified poloxamer 188 for vaso-occlusive episodes in SCD also showed no evidence of nephrotoxicity based on serum creatinine levels. The effects of poloxamer 188 on the kidney are more fully explained in Supplement 3 of our article.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.2021.11097</identifier><language>eng</language><publisher>Chicago: American Medical Association</publisher><subject>Adults ; Albumins ; Children ; Clearances ; Creatinine ; Immunoglobulin G ; Impurities ; Kidneys ; N-Acetylglucosaminidase ; Permeability ; Placebos ; Poloxamers ; Retinol-binding protein ; Sickle cell disease ; Vitamin A</subject><ispartof>JAMA : the journal of the American Medical Association, 2021-09, Vol.326 (10), p.974</ispartof><rights>Copyright American Medical Association Sep 14, 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Kenter, Marcel J H</creatorcontrib><creatorcontrib>Cohen, Adam F</creatorcontrib><creatorcontrib>Gurkan, Umut A</creatorcontrib><creatorcontrib>Casella, James F</creatorcontrib><creatorcontrib>Kronsberg, Shari S</creatorcontrib><creatorcontrib>Gorney, Rebecca T</creatorcontrib><title>Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply</title><title>JAMA : the journal of the American Medical Association</title><description>The EPIC study investigators were aware of the prior cardiac studies cited by Drs Kenter and Cohen suggesting nephrotoxicity due to poloxamer 188. It is important to note that these early studies used commercial-grade poloxamer 188. Subsequent studies showed that removal of impurities from this preparation reduced nephrotoxicity in a rat model and that the isolated impurities caused nephrotoxity. A phase 1 study of the resulting purified poloxamer 188 for acute chest syndrome in 43 participants with SCD focused on safety and included studies of urinary N-acetylglucosaminidase, retinol-binding protein, creatinine and creatinine clearance, albumin, and IgG excretion; participants were followed up for up to 10 days with repeat measurements at 28 to 35 days. The investigators concluded that there were no time-related increases in serum creatinine or creatinine clearance and no evidence of adverse effects on glomerular integrity, permeability, filtration, or proximal or distal tubular function. Phase 2 and 3 studies of purified poloxamer 188 for vaso-occlusive episodes in SCD also showed no evidence of nephrotoxicity based on serum creatinine levels. The effects of poloxamer 188 on the kidney are more fully explained in Supplement 3 of our article.</description><subject>Adults</subject><subject>Albumins</subject><subject>Children</subject><subject>Clearances</subject><subject>Creatinine</subject><subject>Immunoglobulin G</subject><subject>Impurities</subject><subject>Kidneys</subject><subject>N-Acetylglucosaminidase</subject><subject>Permeability</subject><subject>Placebos</subject><subject>Poloxamers</subject><subject>Retinol-binding protein</subject><subject>Sickle cell disease</subject><subject>Vitamin A</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNrdjb1OwzAURg0CifAzs16JOamdNLIzolDEwBDRCsbKJDeqw60dfJMK3p4OPAAz33KGc6RPiFslMyWlWgx2b7Nc5ipTSlb6VCSqLExalJU5E4mUlUn10iwvxCXzII9ThU5OnptA4cvuMYIyBg4MDdkW3wP0IUJjne9nglfLIQ1tSzO7A8JqdBw6ZHAe6p2jLqIH6zu472aaGN7ctIO1az8IoUYieHCMlnHxb8_SFxzp-1qc95YYb355Je4eV5v6KR1j-JyRp-0Q5uiPapuXWpe5yYuq-Fv1A_fpniA</recordid><startdate>20210914</startdate><enddate>20210914</enddate><creator>Kenter, Marcel J H</creator><creator>Cohen, Adam F</creator><creator>Gurkan, Umut A</creator><creator>Casella, James F</creator><creator>Kronsberg, Shari S</creator><creator>Gorney, Rebecca T</creator><general>American Medical Association</general><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20210914</creationdate><title>Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply</title><author>Kenter, Marcel J H ; Cohen, Adam F ; Gurkan, Umut A ; Casella, James F ; Kronsberg, Shari S ; Gorney, Rebecca T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_25775282393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adults</topic><topic>Albumins</topic><topic>Children</topic><topic>Clearances</topic><topic>Creatinine</topic><topic>Immunoglobulin G</topic><topic>Impurities</topic><topic>Kidneys</topic><topic>N-Acetylglucosaminidase</topic><topic>Permeability</topic><topic>Placebos</topic><topic>Poloxamers</topic><topic>Retinol-binding protein</topic><topic>Sickle cell disease</topic><topic>Vitamin A</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kenter, Marcel J H</creatorcontrib><creatorcontrib>Cohen, Adam F</creatorcontrib><creatorcontrib>Gurkan, Umut A</creatorcontrib><creatorcontrib>Casella, James F</creatorcontrib><creatorcontrib>Kronsberg, Shari S</creatorcontrib><creatorcontrib>Gorney, Rebecca T</creatorcontrib><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kenter, Marcel J H</au><au>Cohen, Adam F</au><au>Gurkan, Umut A</au><au>Casella, James F</au><au>Kronsberg, Shari S</au><au>Gorney, Rebecca T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><date>2021-09-14</date><risdate>2021</risdate><volume>326</volume><issue>10</issue><spage>974</spage><pages>974-</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><abstract>The EPIC study investigators were aware of the prior cardiac studies cited by Drs Kenter and Cohen suggesting nephrotoxicity due to poloxamer 188. It is important to note that these early studies used commercial-grade poloxamer 188. Subsequent studies showed that removal of impurities from this preparation reduced nephrotoxicity in a rat model and that the isolated impurities caused nephrotoxity. A phase 1 study of the resulting purified poloxamer 188 for acute chest syndrome in 43 participants with SCD focused on safety and included studies of urinary N-acetylglucosaminidase, retinol-binding protein, creatinine and creatinine clearance, albumin, and IgG excretion; participants were followed up for up to 10 days with repeat measurements at 28 to 35 days. The investigators concluded that there were no time-related increases in serum creatinine or creatinine clearance and no evidence of adverse effects on glomerular integrity, permeability, filtration, or proximal or distal tubular function. Phase 2 and 3 studies of purified poloxamer 188 for vaso-occlusive episodes in SCD also showed no evidence of nephrotoxicity based on serum creatinine levels. The effects of poloxamer 188 on the kidney are more fully explained in Supplement 3 of our article.</abstract><cop>Chicago</cop><pub>American Medical Association</pub><doi>10.1001/jama.2021.11097</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0098-7484 |
ispartof | JAMA : the journal of the American Medical Association, 2021-09, Vol.326 (10), p.974 |
issn | 0098-7484 1538-3598 |
language | eng |
recordid | cdi_proquest_journals_2577528239 |
source | American Medical Association Journals |
subjects | Adults Albumins Children Clearances Creatinine Immunoglobulin G Impurities Kidneys N-Acetylglucosaminidase Permeability Placebos Poloxamers Retinol-binding protein Sickle cell disease Vitamin A |
title | Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease/Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T00%3A24%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Poloxamer%20188%20vs%20Placebo%20for%20Painful%20Vaso-occlusive%20Episodes%20in%20Children%20and%20Adults%20With%20Sickle%20Cell%20Disease/Poloxamer%20188%20vs%20Placebo%20for%20Painful%20Vaso-occlusive%20Episodes%20in%20Children%20and%20Adults%20With%20Sickle%20Cell%20Disease/Poloxamer%20188%20vs%20Placebo%20for%20Painful%20Vaso-occlusive%20Episodes%20in%20Children%20and%20Adults%20With%20Sickle%20Cell%20Disease-Reply&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Kenter,%20Marcel%20J%20H&rft.date=2021-09-14&rft.volume=326&rft.issue=10&rft.spage=974&rft.pages=974-&rft.issn=0098-7484&rft.eissn=1538-3598&rft_id=info:doi/10.1001/jama.2021.11097&rft_dat=%3Cproquest%3E2577528239%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2577528239&rft_id=info:pmid/&rfr_iscdi=true |